Efficacy and Safety of Short Duration of DAPT After GENOSS® DES Implantation in Patients with Coronary Artery Disease

NCT06075420

Status	RECRUITING
Sponsor	Genoss Co., Ltd.
Enrollment	1,000 participants

Key Eligibility Criteria

Inclusion (3)

- Patients of 19 and over
- Patients with coronary artery disease treated with GENOSS SES
- Participants who voluntarily decide to participate in this clinical trial, agree to the study protocol and clinical follow-up plan, and provide written informed consent as study participants

Exclusion (5)

- Patients with cardiogenic shock at the time of hospitalization
- Patients who are pregnant or planning to become pregnant
- Patients with a life expectancy of less than 1 year
- Patients participating in randomized controlled trials using other medical devices
- Patients who have already received treatment with another DES (Drug Eluting Stent) or BMS (Bare Metal Stent) at the time of registration (However, other stent insertions are allowed due to failure of GENOSS DES insertion)

Locations (1 total)

Wonju Severance Christian Hospital, WOnju, Gangwon State, South Korea